Estrogen Receptors As Predictors Of The Effectiveness Of Platinum Agents And Taxanes In Patients With Ovarian Cancer
Objective of the study is to evaluate the clinical significance of the expression of estrogen receptors of different types (ERa and ERfi) in the prognosis of the effectiveness ofplatinum- and taxane-based chemotherapy for ovarian cancer. Materials and Methods. Quantitative assessment of the level of ERa and ERft expression in ovarian cancer tissue was carried out using flow cytofluorometry technique in a patient cohort (n=31) homogenized by following clinical characteristics: stage III high-grade serous ovarian cancer, non-optimal extent ofcytoreduction, 6 cycles of first line platinum- and taxane-based chemotherapy. Results. ERa and ERft expression was revealed in all samples of ovarian cancer with significant heterogeneity of quantitative indicators of the markers in different patients and the excess of the median ofERfi expression was 1,5 times as high as the same indicator for ERa. Analyzing Kaplan -Meier curves for progression-free survival , it was evident that the median ofprogression-free survival was 2 times higher (p = 0,02) and the risk of recurrence was 2,5 times lower (p = 0,04) in the group with high vs low level of ERft expression. Conclusion. A high level of ERft expression in the tumor (in more than 40% of cells) is a predictor of the effectiveness of first line chemotherapy for ovarian cancer based on platinum- and taxane-based agents.